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Abstract 29 
Current treatment for pediatric IBD patients is often ineffective, with serious side effects. 30 
Manipulating the gut microbiota via fecal microbiota transplantation (FMT) is an emerging 31 
treatment approach but remains controversial. We aimed to assess the composition of the fecal 32 
microbiome through a comparison of pediatric IBD patients to their healthy siblings, evaluating 33 
risks and prospects for FMT in this setting. A Case–Control (Sibling) Study was conducted 34 
analyzing fecal samples of six children with Crohn’s Disease (CD), six children with Ulcerative 35 
Colitis (UC) and 12 healthy siblings by metagenomic sequencing.  In addition, lifetime antibiotic 36 
intake was retrospectively determined. Species richness and diversity were significantly reduced in 37 
UC patients compared to control (MWU FDR = 0.011). In UC, bacteria positively influencing gut 38 
homeostasis e.g. Eubacterium rectale and Faecalibacterium prausnitzii were significantly reduced 39 
in abundance (MWU FDR = 0.05). Known pathobionts like Escherichia coli were enriched in UC 40 
patients (MWU FDR = 0.084). Moreover, E. coli abundance correlated positively with that of 41 
several virulence genes (SCC > 0.65, FDR < 0.1). A shift towards antibiotic resistant taxa in both 42 
IBD groups distinguished them from controls (MWU BY FDR = 0.062 in UC, MWU BY FDR = 43 
0.019 in CD). The collected results confirm a microbial dysbiosis in pediatric UC, and to a lesser 44 
extent in CD patients, replicating associations found previously using different methods. Taken 45 
together, these observations suggest microbiotal remodeling therapy from family donors, at least for 46 
children with UC, as a viable option.  47 
New and Noteworthy 48 
In this sibling study, prior reports of microbial dysbiosis in IBD patients from 16S rRNA 49 
sequencing was verified using deep shotgun sequencing and augmented with insights into the 50 
abundance of bacterial virulence genes and bacterial antibiotic resistance determinants, seen against 51 
the background of data on the specific antibiotic intake of each of the study participants. The 52 
observed dysbiosis, which distinguishes patients from siblings, highlights such siblings as potential 53 
donors for microbiotal remodeling therapy in IBD. 54 
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Abbreviations: 59 
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KW Kruskal-Wallis test
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mOTUs metagenomic Operational Taxonomic Units 
MWU Mann-Whitney-U test
PCDAI Pediatric Crohn’s Disease Activity Index
PUCAI  Pediatric Ulcerative Colitis Activity Index
rRNA ribosomal RNA 
SCC Spearman rank Correlation Coefficient
UC Ulcerative Colitis 
 60 
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Introduction 61 
The gut microbiota plays a crucial role in human physiology and host development (41), and 62 
maintaining equilibrium between the commensal microbiota and the host immune system is 63 
required for a healthy gut homeostasis. 64 
There is increasing evidence for a contribution of the gut microbiome to the etiology of IBD (18). In 65 
the past, genome–wide association studies have revealed multiple host gene loci in both UC and 66 
CD, with alleles associated with functional aberrations of the intestinal immune system (18). Recent 67 
studies based on novel DNA sequencing methods have revealed major differences in bacterial 68 
taxonomic composition between IBD patients and healthy individuals (see Appendix Table 1). Still, 69 
it remains unclear whether these observed alterations are the cause or result of inflammation. 70 
Since most studies on the IBD microbiome to date have relied on 16S rRNA sequencing, the 71 
functional impact of the reported dysbiosis is not well understood (23), and reported associations 72 
are largely limited to identifying more general taxa (ranging from bacterial phyla to genera) as 73 
being associated with disease, given the limitations of 16S for reliable species identification Whole 74 
genome sequencing allows higher resolution and sensitivity than the more common and less 75 
expensive 16S rRNA sequencing and offers new insights into the functional context of the IBD 76 
microbiome (e.g. abundance of metabolic pathways and the distribution of genes determining 77 
virulence or resistance to antibiotics).  78 
Current treatment strategies for pediatric IBD patients often come with serious side effects or 79 
provide insufficient treatment responses. Therefore, there is a need for novel treatment approaches.  80 
Manipulating the gut microbiota via fecal microbiota transplantation (FMT) appears as an 81 
intriguingly facile and harmless therapy option for children with IBD. Efficacy in the treatment of 82 
pediatric UC via fecal enemas has been suggested (22), and the administration of FMT via 83 
nasogastric tube has led to improved well-being in pediatric CD patients (44). Still, its outcome 84 
remains controversial, since results from the first two randomized placebo-controlled trials in adults 85 
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are in contradiction (29, 36). While no serious adverse events for FMT in children have been 86 
reported, data on feasibility and safety in a long-term perspective (e.g. the risk of transferring a 87 
pathogenic disease state via FMT) are missing (12). Microbiome-based validation of suitable donors 88 
might help better predict treatment outcome (11). The present pilot study therefore aims to elucidate 89 
microbiome correlates of juvenile IBD so as to help in designing criteria for when FMT might be 90 
employed, using a pediatric cohort of CD and IBD patients as well as their healthy siblings.  91 
Methods 92 
Cohort recruitment 93 
Patients were selected from the IBD patient collective at the Zentrum für Kinder- und 94 
Jugendmedizin (University Children’s Hospital) Mainz in Mainz, Germany. In all patients IBD 95 
diagnosis was histologically confirmed by prior endoscopy. Disease activity was assessed by the 96 
Pediatric Ulcerative Colitis Activity Index (PUCAI) (45) and the Pediatric Crohn’s Disease Activity 97 
Index (PCDAI) (14). In total, fecal samples from six Ulcerative Colitis (UC) patients and six 98 
Crohn’s Disease (CD) patients and from 12 controls were collected from August 2013 to July 2014. 99 
Controls were healthy siblings of the IBD patients, sharing the same parents and living in the same 100 
households, thereby sharing genetic background, environment and diet. In addition, study 101 
participants completed a questionnaire about health/disease status, living conditions, and alimentary 102 
habits. Children who had taken antibiotics during the last 2 months prior to sampling were excluded 103 
from the study. For additional cohort characteristics see Table 1. Since all study participants are 104 
older than 8 years, and thus should have relatively stable microbiomes, we do not anticipate age 105 
differences between patients and healthy siblings to have a strong impact on results. 106 
The study design was approved by the ethics committee of the State Chamber of Physicians of 107 
Rhineland-Palatinate (Ethikkomission der Landesärztekammer Rheinland-Pfalz, reference number 108 
837.292.13 (8977-F)). 109 
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Written informed consent was given by both parents and the study participants prior to sample 110 
collection and medical assessment. 111 
Assessment of lifetime antibiotic intake 112 
Antibiotic intake of the study population was retrospectively recorded, starting from birth. 113 
Therefore, all physicians/hospitals who have treated the study participants were contacted and asked 114 
to transfer their antibiotic prescription data for each child. Out of 306 person years of total 115 
participant lifetime to date, only 16 (5 %) could not be covered by this assessment.  116 
Sample collection 117 
Fecal samples were collected at home with help of a stool sampling kit. The stool sampling kit 118 
consisted of a plastic lining to cover the toilet, two stool sample tubes with spoons, two plastic bags 119 
and a clipping system for safe closure of the outer bag. Collected samples were stored at home 120 
between 4°C and 8°C and transferred to the laboratory within 24h. In the laboratory of the Zentrum 121 
für Kinder- und Jugendmedizin Mainz, Germany, the samples were frozen at – 80°C. All samples 122 
were gathered there and then shipped on dry ice (- 78.5°C) to the European Molecular Biology 123 
Laboratory (EMBL) in Heidelberg, Germany.  124 
Probe processing 125 
All probe processing was conducted by the Genomics Core Facility, EMBL, Heidelberg. DNA-126 
Extraction and Library preparation were performed according to the protocol from Zeller et al. (49). 127 
Whole genome shotgun sequencing was executed on the Illumina HiSeq 2000/2500 (Illumina, San 128 
Diego, USA) platform. All samples were paired-end sequenced with a read length of 100 bp and a 129 
targeted sequencing depth of 5 Gbp (49). 130 
Data analysis 131 
Data analysis was performed at the Structural and Computational Biology Unit, EMBL, Heidelberg. 132 
Taxonomic profiling 133 
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Using the MOCAT pipeline (21), gene sequences were annotated to their bacterial taxonomy. Since 134 
many gut bacteria are known to belong to species for which no genome yet exists in public 135 
databases, two different alignment procedures were used. The first procedure was based on 136 
metagenomic operational taxonomic units (mOTUs) (43) which also encompass uncharacterized 137 
bacteria identified in metagenomic dataset. The second procedure used species clusters defined 138 
from bacterial genomes for which publicly deposited genomes do exist (27). In this manner as 139 
complete coverage of the taxonomic composition of the samples as possible was achieved. 140 
Analysis of bacterial diversity, species richness and evenness 141 
Based on the mOTU taxonomic composition, Shannon diversity index, species richness and 142 
evenness were calculated using the vegan R package (http://cran.r-143 
project.org/web/packages/vegan/index.html), for details see Zeller et al. 2014 (49). 144 
Functional profiling 145 
To gain insight into metabolic functions of the microbiome, the metagenomic catalogue was aligned 146 
to the Kyoto Encyclopedia of Genes and Genomes (KEGG) Database (16). For further details see 147 
Zeller et al., 2014 (49). 148 
Identifying virulence factors 149 
For virulence factor profiling of the metagenome samples, reads were mapped to virulence factor 150 
gene families via an annotated gene catalog as described in Kultima et al., 2016 (20). For each gene 151 
catalog entry annotated to a virulence factor gene family, we traced which sequenced taxa have 152 
genes similar enough to the reference that reads originating from them could map to it. For the 153 
virulence genes found significantly different under IBD in this study, from sequence alone their 154 
specific origin cannot be determined; on average each virulence gene family is found in 87 taxa 155 
(See Supplementary Table 2). 156 
Identifying antibiotic resistance genes 157 
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To estimate the abundance and prevalence antibiotic resistance genes in the studied microbiomes, 158 
the reference gene catalogue was aligned to the Antibiotic Resistance Genes Database (ARDB)(25), 159 
as described in Forslund et al. (9). Metronidazole resistance genes (nim, nimA, nimB, nimC, nimD, 160 
nimF) were further annotated through bidirectional best hits between the reference gene catalog and 161 
all annotated such sequences from UniProt, otherwise as previously described. Only antibiotic 162 
classes which had been taken by at least one individual in the study cohort were considered.  163 
For each sample, three measures of antibiotic resistance gene carriage were determined: the raw 164 
relative abundance of antibiotic resistance genes, the relative abundance of potentially resistance 165 
gene-carrying bacterial species, and the antibiotic resistance potential (abundance of antibiotic 166 
resistance genes relative to the abundance of potentially resistance gene-carrying species). The 167 
abundance of potentially resistant species was calculated as the fraction of genetic material from 168 
each sample that map to species belonging to genera with known examples of species carrying 169 
resistance genes of the appropriate type, in the reference genome database used (see Forslund et al. 170 
(9)). 171 
Statistical analysis 172 
In subsequent analyses, all read/base counts were transformed into relative abundances (by division 173 
by the total number of reads/bases sequenced per sample) as described previously by Zeller et al., 174 
2014 (49).  175 
In order to identify significant differences between sample categories for each metagenomic feature, 176 
a nonparametric Kruskal-Wallis-test (KW) was performed whenever the UC-, CD- and control-177 
group were compared. This was followed by pairwise Mann-Whitney-U-tests (MWU) as a post-hoc 178 
procedure. 179 
For data sets not normally distributed, the Wilcoxon signed-rank test was employed to compare sib 180 
pairs directly. Correlation analyses were performed using Spearman rank’s correlation coefficient 181 
(SCC), in order to fit potentially non-normal data. 182 
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In cases of multiple testing p-value correction via the Benjamini-Hochberg false discovery rate 183 
(FDR)(2) or the Benjamini-Hochberg-Yekutieli procedure (BY) (3) was performed. For corrected p-184 
values significance threshold was set at < 0.5; corrected p-values ranging 0.05 < FDR < 0.1 we refer 185 
to as approaching significance. 186 
To reduce the number of tests for taxonomic abundances and thereby increase statistical power, a 187 
pre-selection of hypotheses was applied by collecting microbiome associations described in the 188 
literature, including taxa directly associated with IBD or associations projected from such reports by 189 
phylogenetic relationships. This collection consisted of all directly reported IBD-associated taxa in 190 
the referenced works and their containing taxonomic superclades (see Appendix Table 1). In 191 
addition, thus far uncharacterized taxa sorting immediately under each clade previously reported 192 
associated with IBD were added, to account for incompleteness of sequenced genomes (e.g. 193 
unknown Firmicutes for class analysis, as Firmicutes were reported to be different on the Phylum 194 
level, or unknown Clostridia for analysis on the order level, as Clostridia were previously reported 195 
to be associated with IBD on the class level); the mOTU technology used here was explicitly 196 
designed to allow detection of unculturable human gut taxa.  197 
A likelihood ratio test (LRT) was conducted to test whether the abundance of potentially resistant 198 
species can be explained by antibiotic selection pressure (as represented through lifetime antibiotic 199 
intake) or not. To calculate these likelihood ratios, mixed-effect linear models taking into account 1) 200 
overall lifetime antibiotic intake and disease status, 2) lifetime antibiotic intake alone, 3) disease 201 
status alone and 4) solely a background constant model were compared to each other. Prior to this 202 
analysis in each case the general assumptions for linear models were tested (independence, absence 203 
of co-linearity, homoscedasticity, linearity and normality of the residuals and absence of influential 204 
data points) using graphpad (http://graphpad.com/quickcalcs/PValue1.cfm) with p-values calculated 205 
for a χ2-distribution with one degree of freedom. 206 
Results 207 
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Pediatric UC patients have reduced microbial biodiversity compared to their healthy siblings 208 
Tests were conducted on the Shannon diversity index to characterize overall gut biodiversity. Only 209 
in UC patients reduction of biodiversity reached significance compared to controls (MWU, nUC = 210 
6/nControl = 12, FDR = .011) (Figure 1). Analyzing the data on aggregate, children with UC and CD 211 
both displayed significantly reduced species richness (MWU, nUC = 6/ nCD = 6/ nControl = 12, FDR = 212 
.011, FDR= .045 respectively) (Figure 1) compared to the set of control children. This reduction 213 
was significant also when matching each IBD patient to their control sibling in a pairwise test (WT, 214 
nUC = 6/ nCD = 5/ nControl = 11, FDR= .048). Similar observations could be made for microbial 215 
community evenness (see Figure 1). 216 
Differences in taxonomic abundances from former 16S rRNA analyses are validated by WGS 217 
Considering those bacterial taxa previously noted as being altered in prevalence or abundance in 218 
IBD (cf Appendix Table 1), many of these findings could be recaptured as significant in the present 219 
cohort even with its limited size, comparing the set of all controls to the set of each subset of IBD 220 
subjects (Figure 2). Pairwise testing of siblings (Wilcoxon rank test) showed the same trends as the 221 
aggregated case-control comparison, though due to limited sample numbers, approached 222 
significance only for associations of Clostridium (Clostridiacae) and Eubacterium rectale to IBD 223 
(Supplementary Table 1).  224 
If we do not restrict analysis to validation of 16S results only, power is reduced due to the increased 225 
number of tested hypotheses. However, 55% (17 out of 31) of the findings described above also 226 
show associations with IBD approaching significance without such preselection and with 227 
subsequently more stringent FDR correction (Supplementary Table 3). The previously described 228 
associations constitute the majority of significant associations found in the unrestricted search, 229 
suggesting most obvious associations already were reported at least once from 16S data. However, 230 
another four taxa approached significance in the unrestricted test, which had not previously been 231 
linked to IBD. On the taxonomic order level, a group of uncharacterized Firmicutes were 232 
11 
 
diminished in the UC population compared to the healthy cohort. At the level of bacterial genera, 233 
Anaerococcus (MR (Control) 10.83, MR (UC) 18.33, MR (CD) 10.00, KW FDR = .093) and a thus far 234 
uncharacterized genus belonging to Clostridiales (MR (Control) 17.08, MR (UC) 5.83, MR (CD) 10.00, 235 
KW FDR = .093), differed in abundance between IBD subjects and controls. Most importantly, 236 
Clostridium ramosum was significantly enriched in UC patients compared to the set of controls 237 
(FDR <.001). 238 
Enrichment of pathobiont species and depletion of commensals 239 
Reduction of gut homeostasis positively influencing E. rectale and Faecalibacterium prausnitzii 240 
were observed in UC and CD samples compared to the set of controls samples, but only the 241 
comparison between control and UC samples approached significance (Figure 2). Similarly, the 242 
pathobiont Escherichia coli was increased in abundance in both IBD conditions, but approached 243 
significance only for UC samples (Figure 2). An increase in Ruminoccus gnavus approached 244 
significance (at the species cluster level, not significant at mOTU level). Bilophila wadsworthia was 245 
decreased in UC, also approaching significance. The pathogen Fusobacterium nucleatum (resolved 246 
at the species cluster level, not significant at mOTU level) was found in IBD patients but not in the 247 
healthy siblings, with this difference approaching significance for UC patients (Figure 2). 248 
The abundance of specific virulence factors correlates with the abundance of certain bacterial 249 
species 250 
Figure 3 gives an overview of the specific virulence genes, which were significantly increased in 251 
the UC population (CD and UC samples compared to the full set of control samples) of the present 252 
study. To identify correlations with species present in the study cohort, a Spearman correlation 253 
analysis was conducted. Most virulence factors were correlated (Spearman test FDR < 0.1) with 254 
abundance of E. coli. All of these genes, except hslT, were previously described and identified as 255 
occurring in strains of E. coli (see Supplementary Table 2). 256 
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Abundance of certain families of genes facilitating the survival of bacteria within macrophages and 257 
the evasion of immune response correlated with abundance of particular gut microbial species 258 
(Bacteroides vulgatus/Gemella morbillorum). Virulence genes adhD, aslA, sitA, Ndk, fur, gcvT and 259 
fepA had no significant correlation with any species found significantly different in abundance 260 
between controls and IBD patients. These observations suggest a broader involvement of those 261 
genes in UC pathogenesis, such that they may play a role which is not reducible to a simple 262 
taxonomic difference.  263 
Abundance of GABA shunt genes is elevated in the IBD microbiome 264 
A Kruskal-Wallis test was performed to analyze KEGG pathways and KEGG modules for 265 
significant differences in gene abundance comparing all IBD cases to all controls. Only the KEGG 266 
module representing the GABA (gamma-Aminobutyric acid) shunt, considered a potential virulence 267 
factor by some investigators (8), showed such a significant difference with a mean rank of 6.67 for 268 
the Control group, 18.67 for UC and 18.00 for CD; BY <.000. 269 
Little difference in antibiotic intake 270 
Neither the cumulative lifetime antibiotic intake per person nor the mean antibiotic intake per life 271 
year was significantly different comparing the full groups of control, UC and CD.  272 
In all three groups cephalosporin was the most commonly prescribed antibiotic, followed by 273 
penicillin, with highest intake for both in the CD group (Figure 4). Metronidazole was only taken 274 
by IBD patients, and a tetracycline antibiotic was only taken once by one subject in the control 275 
group.  276 
The resistome of IBD patients and their healthy siblings 277 
In accordance with previous studies (9), tetracycline was the antibiotic for which the most 278 
resistance capacity was found in the microbiomes of the study cohort (Figure 5), followed by 279 
cephalosporin. No significant difference in the abundance of resistance genes against any antibiotic 280 
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class was observed comparing the full groups of control, UC and CD samples on aggregate (See 281 
Appendix Figure 1). While we augment the ARDB antibiotic resistance gene database with known 282 
resistance genes for metronidazole, the antibiotic most commonly prescribed to IBD patients, such 283 
genes are still largely uncharacterized. As a result, it is possible we fail to observe an association 284 
between such resistance and metronidazole exposure history.  285 
The high relative fraction of potentially resistant bacterial species does distinguish the gut 286 
microbiome of IBD patients from the microbiomes of controls. Higher abundances of bacterial 287 
species where strains with resistance genes have been sequenced were observed for all antibiotic 288 
classes (BY FDR = 0.062 for UC; BY FDR = 0.019 for CD) (Fig. 5, see also Appendix Figure 1). 289 
To evaluate whether this high abundance of potentially resistant species was due to antibiotic 290 
selection pressure, a likelihood ratio test was performed testing fits of the data to nested mixed-291 
effects linear models. The total abundance of potentially resistant species was modeled from overall 292 
lifetime antibiotic intake of each individual together with disease status (Control, UC, CD). A model 293 
including both antibiotic intake and disease status did not fit significantly better than a model 294 
including group affiliation alone (LRT test, P > 0.4). We therefore at this point cannot refer the 295 
greater relative prevalence of potentially resistant microbial taxa in the IBD patients than in their 296 
healthy siblings' microbiomes to any higher lifetime antibiotic consumption in these children. 297 
Discussion  298 
Our results from comparatively analyzing the microbiome of pediatric IBD patients constitute a 299 
deep sequencing-based consolidated validation of findings from previous research which relied 300 
mostly on 16S rRNA sequencing (see Appendix Table 1 and Supplementary Table 1). To our 301 
knowledge, this is the first study which contrasts metagenomic analysis of antibiotic resistance 302 
genes in relation to lifetime antibiotic intake of study participants in an IBD cohort. We also provide 303 
the first direct metagenomic functional profiling of pediatric IBD samples, including analysis of 304 
virulence factor differential abundance in cases versus controls. By a study design using as controls 305 
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healthy siblings of IBD participants sharing similar diet and living circumstances, we are able to 306 
minimize potential confounding factors. In addition, although we expected higher antibiotic 307 
consumption within the patient population, which could have provided an alternate interpretation of 308 
the observed dysbiosis, antibiotic intake was not significantly higher among pediatric IBD patients 309 
than other children. 310 
Dysbiosis of the intestinal microbiome may involve reduced microbial diversity, enrichment of 311 
potentially pathogenic taxa and/or depletion of beneficial microbiota (31). Microbial dysbiosis has 312 
been observed in numerous disease conditions, e.g. colorectal carcinoma (40), hypertension (48), 313 
psoriatic arthritis (37), diabetes mellitus type 1 (42) and type 2 (17) and especially in pediatric IBD 314 
(see Appendix Table 1). 315 
Several research groups observed how microbial diversity and the amount of beneficial commensals 316 
is reduced in the microbiome of both pediatric IBD conditions (10, 28, 39). At the same time, 317 
potential pathobionts like E. coli are more prevalent in the IBD microbiome. These findings are 318 
quantifiable using the present setup and we were able to validate them. While in the present study, 319 
we find more microbiome associations of UC than of CD, previous studies found stronger such 320 
associations to CD (see Appendix Table 1 and Supplementary Table 1). As we observe similar 321 
trends in both IBD subtypes for most comparison, we interpret this as that our small sample size 322 
may make us underpowered to detect many of the associations to CD, which larger studies using 323 
similar methodology may be able to recover. 324 
Decrease of gut homeostasis-promoting species in the IBD microbiome 325 
The gut homeostasis-promoting bacterial species F. prausnitzii and E. rectale were depleted in both 326 
IBD conditions in the present cohort. This observation is in consensus with former microbiome 327 
analysis of UC and CD patients relying on 16S rRNA sequencing (6, 10, 26). Both species are 328 
important producers of short-chain fatty acids (SCFA), including propionate and butyrate (34). 329 
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SCFAs are among the most central metabolites produced by microbes, influencing both colon 330 
physiology and the intestinal immune system (30). 331 
Increase of E. coli and F. nucleatum in pediatric IBD 332 
In contrast, pathobionts such as E. coli and F. nucleatum were enriched in the IBD microbiome. 333 
This is in agreement with former 16S rRNA analyses, where E. coli was increased in the IBD 334 
microbiome (6, 28, 39). E. coli, especially its subspecies adherent-invasive E. coli (AIEC), has been 335 
directly implicated in IBD development (23). A strong correlation was observed between E. coli 336 
abundance and that of genes implicated in the expression of fimbriae or leading to the adhesion of 337 
bacteria to the intestinal mucosa. Those genes are characteristic of pathogenic E. coli. subspecies 338 
(e.g. enterohaemorrhagic, uropathogenic E. coli) (1, 5). However, most of these genes are found 339 
also in many other bacterial taxa, and as such it cannot be ruled out that other bacterial species also 340 
may contribute to the observed increase of virulence capacity in IBD patients (see Supplementary 341 
Table 2).  342 
The strong correlation of the abundance of virulence genes enriched in the UC microbiome with E. 343 
coli abundance suggests that this species is a central driver of a functional shift towards virulence in 344 
UC patients of the present cohort, underscoring its potential role as an IBD partial cause. 345 
Survival strategies of bacteria – relating virulence capacity to pathology 346 
The virulence genes enriched in the UC microbiome included TonB, sitA, IroN, fepA and Fur. They 347 
are all genes implicated in metal acquisition of Enterobacteria, where the last is the key regulator of 348 
iron transport systems (33). The enriched iron uptake/transport systems contribute to the virulence 349 
of their host bacteria by counteracting the so called nutritional immunity which deprives bacteria of 350 
iron. The homeostasis of intracellular iron concentrations is maintained by Fur (the ferric uptake 351 
regulator), since high intracellular accumulation also is toxic for the bacteria (32). In its role as a 352 
sensor for iron availability, Fur is also able to regulate directly or indirectly (through iron 353 
concentration) the expression of several other virulence factors in pathogenic bacteria.  354 
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Adaptation of microbes in IBD to a lower environmental pH, as a feature of inflammation, is 355 
reflected by higher abundance of the genes encoding the GABA shunt module in the IBD 356 
microbiomes studied here (Figure 4B). The GABA shunt supplies bacteria with nitrogen and 357 
promotes their survival in acidic conditions and other environmental stresses (8). Feehily and 358 
Karatzas therefore suggested that this module could facilitate microbial pathogenicity. 359 
Exploration of the IBD resistome in correlation with antibiotic consumption 360 
Several studies have displayed a significant relation of antibiotic intake in childhood with the later 361 
development of IBD, particularly Crohn’s Disease (13, 19, 47). Analogously, antibiotic 362 
consumption often exacerbates dysbiosis, seen as a reduced species richness and the bloom of 363 
pathogens (e.g. Clostridium difficile) in the gut microbiome (46). In addition, administration of 364 
antibiotics not only leads to shifts in taxonomic composition, but also induces the lateral transfer 365 
and spread of antibiotic resistance genes in a microbial ecosystem (38). 366 
Notably, the quantification of antibiotic resistance genes in the microbiomes of the present cohort 367 
revealed no significant difference in the relative abundance of these genes between IBD patients 368 
and their healthy siblings, and similar retrospective assessments of antibiotic intake in both groups. 369 
In other words, while it seems unlikely the IBD discordance within the sib pairs can be explained by 370 
differences between siblings in antibiotic exposure, the possibility remains that the families 371 
themselves differ from other families in both antibiotic exposure and IBD prevalence, highlighting 372 
the inter-sibling differences in microbiome composition as rather reflecting IBD risk keeping 373 
antibiotic exposure constant. It is further conceivable that resistant bacteria acquired from intra-host 374 
adaptation to antibiotic treatment or from healthcare setting exposure may propagate between 375 
family members living in close contact. In contrast, a significant shift in both IBD conditions 376 
towards a higher abundance of species potentially carrying antibiotic resistance genes was revealed. 377 
This measure could not be reliably predicted from individual antibiotics use history within the 378 
present dataset, however. 379 
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Besides antibiotic treatment, intake of IBD medications has recently been lined out as a covariate of 380 
microbiome variation in a large-scale study (7). Due to cohort size, we had not the power to detect 381 
such effects, although they need to be assumed (Table 1).  382 
Clinical implementation of study results – are siblings suitable donors in FMT? 383 
It has been argued whether or not siblings or near relatives are suitable choices for donors in FMT, 384 
because they share genetic and environmental risk factors with the patients (4). A recent study on 385 
the IBD microbiome in pediatric patients and their first-grade family members suggested a disease-386 
related microbial and metabolomic state in some relatives, suggesting this risk may be relevant (15). 387 
Moreover, Li et al. (24) recently outlined the importance of the compatibility of the donor and 388 
recipient microbiomes to receive persistent responses from FMT treatment. They concluded that 389 
each recipient will need an idiosyncratic donor to attain successful colonization by allogenic strains. 390 
Donor strains will colonize more successfully when the species is already present in the recipient 391 
microbiome. In the present study, gut microbial diversity (Shannon diversity index) and particularly 392 
species richness was significantly diminished in IBD patients when comparing each patient with 393 
their sibling. This observation of overall dysbiosis in pediatric IBD suggests that healthy siblings, 394 
who have more analogy than total strangers, but still provide a healthier microbiome composition, 395 
may indeed be suitable as donors from an efficacy point of view.  396 
Future outlook 397 
This study must be considered a pilot effort, by design and given the limited number of subjects 398 
included. A future study with more pediatric IBD patients and healthy siblings would yield greater 399 
statistical power and will hereby provide both further validation (esp. intra-sibling disparity) and the 400 
potential discovery of novel associations, which was very limited at the present time for gut 401 
microbial taxonomic correlates of IBD, as our research was mainly based on previous 16S rRNA 402 
findings (Appendix Table 1). Likewise, it would be very interesting to further employ direct sib pair 403 
comparisons, e.g. regarding the analyses of virulence and resistance genes. However, in the present 404 
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study the efficacy of direct sib pair comparison was limited for reasons of statistical power, and 405 
most analysis therefore relied on aggregated analysis (comparing the sets of all control samples to 406 
the samples in the UC/CD-cohorts), obscuring intra-sibling disparity. The additional analysis of 407 
tissue samples should be considered in the future, as recent research has demonstrated a discrepancy 408 
between luminal and mucosal samples in microbial composition (35) and as deep sequencing of 409 
bioptic samples is becoming more feasible. Today, a crucial limitation inherent to all functional 410 
metagenomic studies, excluding those using direct selection, is that only known gene families can 411 
be quantified for generation of functional profiles. Consequently, it is possible that results are 412 
reflecting research biases e.g. virulence factors to be better known in some taxa than others. With 413 
databases of curated resistance determinants growing in scope, and with technologies for large-scale 414 
functional screen metagenomics gradually maturing, these difficulties should decrease in coming 415 
years. We anticipate further studies building on top of what is reported here. 416 
 417 
Conclusion  418 
Our observations of dysbiosis, higher abundance of virulence factors and a shift towards gut 419 
bacterial taxa with known resistance gene carrying strains in the IBD population provide evidence 420 
for siblings as appropriate potential stool donors for FMT treatment of afflicted children. Pediatric 421 
IBD patients differ from their healthy siblings in several regards that can be linked to the disease. 422 
Employing such siblings as donors would further facilitate the possibility of “home-done” 423 
transplantation. Furthermore, the ethical, esthetic and clinical barriers against stool transplants 424 
likely are easier to overcome with respect to a close relative donor than in the case of an outside / 425 
adult stool donor. The same holds regarding considerations of the potential transmission of 426 
infectious diseases and the adaptations of the microflora to dietary habits, where siblings dwelling 427 
in the same home already should be similar. 428 
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Finally, our observations suggest utility of taking metagenomic measurements of microbial 429 
dysbiosis in both donor and recipient pre- and post-procedure in order to correlate FMT outcome 430 
with microbiome characteristics.431 
20 
 
Appendix  432 
Appendix Table 1: Bacteria found associated with inflammatory bowel diseases by previous work groups = literature selection. 433 
↑/↓ = increase/decrease in patients with IBD in comparison with healthy controls; ↑CD /↓CD = increase/decrease in patients with Crohn’s Disease; ↑UC /↓UC = increase/decrease in patients with Ulcerative Colitis; 434 
Superscripted numbers are referring to the authors, see reference table below. 435 
Phylum Class Order Family Genus Species
Bacteroidetes ↓2↑4,8 
↑CD5  
Bacteroidetes Bacteroidales ↓CD6 Porphyromonadaceae Odoribacter ↓1 
Parabacteroides ↓CD6 
 
Bacteroidaceae Bacteroides ↑8↓17↓CD6 B. thetaiotaomicron ↓2 B. 
vulgatus ↓CD6  
B. caccae ↓CD6
Prevotellaceae Prevotella ↓UC3  
Rikenellaceae ↓CD6 Alistipes  
Firmicutes ↓2,4 ↓UC14 Clostridia ↓UC14↓CD3,17 
 
Clostridiales ↓CD3,6 
 
Lachnospiraceae↓1, 2 
↓CD6  
 
Roseburia ↓1↓CD3,6 
 
R. hominis ↓UC 7 
R. faecis ↓CD5 
R. intestinalis ↓CD6s
Coprococcus ↓CD6 C. eutactus ↓CD5 
C. comes ↓CD6s
Clostridiaceae  Clostridium ↓8  C. leptum↓9 
C. nexile↓CD6s 
C. bolteae ↓CD6s
Blautia ↓CD6s  B. coccoides↓9 
B. hanseni↓CD6
Dorea ↓CD6  
Butyricicoccus  B. pullicaecorum 1 ↓16
Ruminococcaceae 
↓CD1,3,5,6 
Acetivibrio 1  
Ruminococcus ↓CD1 
↓CD6 
R. gnavus ↑CD3↓CD6 
R. torques ↓CD6
Faecalibacterium↓1 ↑CD 
10 ↓CD3,6,11,17,19 ↓UC12 
F. prausnitzii ↓UC 7↓CD6 
↓CD9
Oscillospira ↓CD5,6   
Subdoligranulum ↓CD5  
Peptococcaceae↓CD3 Peptococcus ↓CD3  
Phascolactobacterium 
↓1 
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Phylum Class Order Family Genus Species
Eubacteriaceae Eubacterium E. rectale ↓CD6
Bacilli ↑CD3 Lactobacillales↓17↑CD3 Leuconostocaceae 
↓UC1 ↑CD3 
  
Lactobacillaceae Lactobacillus ↑13↑ CD3,6   
Streptococcaceae↓UC3 Streptococcus↑CD6↓UC3  
Enterococcaceae Enterococcus ↑ CD6  
Gemellales Gemellaceae ↑ CD6 Gemella G. morbillorum ↑ CD6
Erysipelotrichi ↑UC14 Erysipelotrichiales Erysipelotrichiaceae 
↓CD6 ↑ CD6s 
Catenibacterium ↓UC3  
Negativicutes Selenomonadales Acidaminococcaceae Acidaminococcus ↑CD3  
Veillonellaceae↑ CD6  Veillonella ↑CD3 V. parvula ↑ CD6
 Dialister ↓CD6  
Actinobacteria ↑2 Actinobacteridae Bifidobacteriales Bifidobacteriaceae↓CD6 
↑CD6 
Bifidobacterium ↓1,11↑13 
 
B. bifidum ↓CD6 
B. longum ↓CD6 
B. adolescentis↓CD6 
B. dentum ↓CD6 
B. infantis
Coriobacteridae Coribacteriales Coriobacteriaceae 1   
Proteobacteria ↑2↑UC14 
↑CD3,5 
Gammaproteobacteria 
↑UC14 ↑CD3 
Enterobacteriales 
↑18↑CD3 
Enterobacteriaceae 
↑CD3,4,6  
Escherichia ↑1↑CD19 E. coli ↑CD6s ↑9,11↑UC14 
AIEC↑ 1↑CD15
Shigella ↑1 ↑CD3,19  
Aermonadales Aeromonadaceae ↑CD3 Aeromonas ↑CD3  
Pasteurellales Pasteurellaceae↑ CD6 Haemophilus (spp.) ↑ 
CD6 
H. parainfluenzae↑ CD6
Betaproteobacteria Neisseriales  Neisseriaceae ↑CD6  Eikenella  E. corrodens ↑ CD6
Burkholderiales Sutterellaceae Sutterella ↓CD6  
Deltaproteobacteria  Desulfovibrionales Desulfovibrionaceae  Bilophila ↓CD6 B. wadsworthia ↓20
Desulfovibrio  
Alphaproteobacteria  Rhizobiales ↑CD5 Bradyrhizobiaceae↑CD5   
Fusobacteria 
↑CD3↑UC14 
Fusobacteria ↑CD3 Fusobacteriales ↑CD3 Fusobacteriaceae 
↑CD3,6 ↓CD6  
Fusobacterium ↑CD3 F. nucleatum ↑ CD6
Spirochaetae Spirochaetes ↑UC14 Spirochaetales    
Verrucomicrobia↓UC14,18 Verrucomicrobiae ↓UC18 Verrucomicrobiales 
↓UC18 
Verrucomicrobiaceae 
↓UC18 
  
Lentisphaerae ↓UC14      
Tenericutes ↓3 Mollicutes ↓3 Anaeroplasmatales ↓3 Anaeroplasmataceae ↓3 Asteroleplasma ↓3  
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Ref-Nr. Author Methods Study cohort 
1 Morgan et al., 2012 • 16S rRNA-sequencing 
• WGS of 11 fecal samples 
• 121 CD  
• 75 UC  
• 27 Controls 
•  Age: 13-45 y 
2 Frank et al., 2007 • Q-PCR -rRNA sequencing • 190 CD, UC, Controls 
3 Willing et al., 2010 • 16S rRNA-sequencing • 29 CD 
• 16 UC  
• 35 Controls 
• Age: 40-67 y 
4 Walker et al., 2011 • 16S rRNA- sequencing • 6 CD 
• 6 UC 
• 5 Controls 
• Age: 24-73 y 
5 Kaakoush et al., 2012 
• 16S rRNA- sequencing • 19 CD (n.o.) 
•  21 Controls 
• Age: 5-15 y 
6 Gevers et al., 2014 • 16S rRNA-sequencing  
• WGS of 43 Fecal samples  
• 447 CD (n.o.) 
• 221 Controls 
• Age: 3-17 y 
7 Machiels et al., 2013 • 16S rRNA sequencing • 127 UC 
• 87 Controls 
8 Andoh et al., 2011 • 16S rRNA sequencing • 31CD 
• 31 UC 
• 30 Controls 
9 Duboc et al., 2013 • 16S rRNA-sequencing • 12 CD 
• 30 UC 
• 29 Controls 
• Age: 20-60 y 
10 Hansen et al., 2012 • 16S rRNA-sequencing • 13 CD 
• 12 UC 
• 12 Controls 
• Age: Children 
11 Schwiertz et al., 2010 
• 16S rRNA-sequencing  • 69 IBD 
• 25 Controls 
• Age: 1-20 
12 Varela et al., 2013 • qRT-PCR • 116 UC patients  
• 29 first degree relatives 
• 31 Controls 
• Age  18–75 y 
13 Wang et al., 2014 • 16S rRNA-sequencing • 36 CD 
• 63 UC 
• 21 Controls 
14 Michail et al., 2012 • 16S rRNA-sequencing • 27 UC 
• 26 Controls 
• Mean Age: 13,5 y 
15 Martinez-Medina et al., 2009 
• Colony dependent Rep-PCR 
• Pulsed field gel electrophoresis  
• Adhesion and invasion assays  
• 20 CD 
• 28 Controls 
16 Eeckhaut et al., 2013 • 16S rRNA-sequencing  
• 51 CD  
• 91 UC  
• 88 Controls 
• Mean Age: 40 y 
17 Aomatsu et al., 2012 • 16S rRNA gene sequencing 
• T-RFLP- analysis 
• 10 CD  
• 14 UC  
• 27 Controls 
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Ref-Nr. Author Methods Study cohort 
• Age: 1-18 y 
18 Papa et al., 2012 • 16S rRNA-sequencing  • 23 CD  
• 43 UC  
• 24 Controls 
• Mean Age: 13 y 
19 Thorkildsen et al., 2013 
• 16S rRNA-sequencing 
 
• 30 CD  
• 33 UC  
• 33 Controls 
• Mean Age: 33 y 
20 Jia W et al., 2012 • PCR of the dsrAB gene  
• 20 CD 
• 14 UC 
• 18 Controls 
 436 
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Appendix Figure 1 492 
 493 
Appendix Figure 1: Antibiotic resistance potential for the different classes of antibiotics which have been used by 
the study population. The antibiotic resistance potential is shown as box plots. No significant difference in antibiotic 
resistance potential was observed.
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Figure Captions 660 
Figure 1: Shannon diversity index, species richness and evenness in comparison between groups (CTRL, 661 
UC, CD). Boxplots show all samples contrasted with MWU tests, showing significances as +: FDR < 0.1, *: 662 
FDR < 0.05. Scatterplots show each sib pair, revealing significantly higher diversity of each type in controls 663 
than in siblings with IBD. 664 
Figure 2:  665 
A) Taxonomic distribution of bacterial taxa in relation to their relative abundance compared between the 666 
control cohort and both IBD populations (UC = Ulcerative colitis; CD = Crohn’s disease). Nodes represent 667 
taxa. Node color indicates direction of associations, with white nodes marking cases where an association 668 
from Appendix Table 1 could not be validated in the novel dataset (see bottom of figure for colour key). 669 
Coloured nodes with a narrow edge represent associations from the literature set (Appendix Table 1) which 670 
approached significance (MWU FDR < 0.1) when testing only hypotheses from this set. Coloured nodes with 671 
a bold edge represent such associations which also approached significance (MWU or KW FDR < 0.1) 672 
without restricting the hypothesis space. Coloured nodes with a bold, dashed outer edge represent IBD 673 
associations approaching significance (MWU or KW FDR < 0.1) when testing all possible associations, 674 
which are novel relative to the set of previous literature-derived findings.  Detailed FDR scores and results 675 
from sibpair testing are given in Supplementary Table 1. Abbreviations: E. rectale = Eubacterium rectale, R. 676 
gnavus = Ruminococcus gnavus, F. prausnitzii = Faecalibacterium prausnitzii, C. ramosum = Clostridium 677 
ramosum, F. nucleatum = Fusobacterium nucleatum, E. coli = Escherichia coli, B. wadsworthia = Bilophila 678 
wadsworthia.  679 
B) Box plots of relative abundance of species in % (square root scale for visibility) for which differences in 680 
abundance approached significance (* indicates MWU FDR < 0.1) in this cohort, comparing the sets of 681 
UC or CD samples to the set of Controls. Detailed FDR scores and results from sibpair testing are given in 682 
Supplementary Table 1. The observed species-level increase of C. ramosum in UC compared to controls is 683 
novel relative to the set of literature-derived findings. 684 
Figure 3: Correlation of species abundance with the abundance of virulence genes significantly increased 685 
in the microbiomes of UC patients. Dark colored = positive correlation of species abundance and the 686 
abundance of the corresponding virulence gene (SCC > 0.65, FDR < 0.1), red = increase of the species 687 
31 
 
abundance in UC patients (MWU, FDR < 0.1), blue = no significant difference of abundance of species 688 
between UC and Control. 689 
Figure 4: Mean lifetime number of antibiotic courses in comparison between Control, Ulcerative colitis 690 
(UC) and Crohn’s disease (CD). Bar charts are divided into segments representing the different antibiotic 691 
classes covered. For the most frequently used antibiotics, mean lifetime number of therapies are indicated. 692 
Figure 5: Fraction of potential carrier species: For relative abundance of potentially resistant species, 693 
significant difference was observed for each antibiotic class between control and Ulcerative colitis (UC) (BY 694 
FDR = 0.062) and control and Crohn’s disease (BY FDR = 0.019). 695 
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Table 1: Cohort characteristics 696 
Characteristics UC CD Control 
n = 6 6 12 
Demographics  
male: female 2:4 3:3 6:6 
Age (years)  
Median ± SD 13 ± 2.7 14 ± 2.0 12.5 ± 3.6 
Range 10 - 17 11 - 16 8 – 20 
BMI (z-score)  
Median ± SD -0.09 ± 0.73 -0.10 ± 1.09 0.26 ± 1.10 
< -1 (%) 0 34 25 
> +1 (%) 17 0 34 
Age at onset (years)  
Median ± SD 9.5 ± 2.8 10 ± 1.8  
Range 4 - 12 9 - 14  
Disease duration (months)  
Median ± SD 22.5 ± 54.4 29 ± 31.6  
Range 13 - 144 0 - 82  
Disease activity  
inactive 3 1  
mild 1 2  
moderate-severe 2 3  
Medications (%)  
Steroids 67 50  
Anti-TNF 17 50  
Azathioprine 50 34  
Mesalazine 50 17  
TGF-β2 0 34  
UDCA 34 0  
Colchizine 17 0  
UC = Ulcerative colitis, CD = Crohn’s disease; % = per group (UC, CD, Control); Disease activity based on PUCAI, 697 
PCDAI, respectively; Anti-TNF = infliximab/adalimumab; TGF-β2 = transforming growth factor beta 2 nutritional support 698 
formula; UDCA = ursodeoxycholic acid 699 
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